NCT04224272View on ClinicalTrials.gov

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 10, 2020

Primary Completion Date

April 28, 2023

Study Completion Date

June 30, 2025

Conditions
HER2+/HR+ Breast Cancer
Interventions
DRUG

ZW25 (Zanidatamab)

Administered intravenously

DRUG

Palbociclib

Administered orally

DRUG

Fulvestrant

Administered as an intramuscular injection

Trial Locations (13)

28034

Hospital Ruber Internacional, Madrid

29010

Hospital Universitario Virgen de la Victoria, Málaga

37203

Sarah Cannon Research Institute, Nashville

41013

Hospital Universitario Virgen del Rocío, Seville

46010

Hospital Clínico Universitario de Valencia, Valencia

90404

UCLA Hematology/Oncology Parkside, Santa Monica

98109

Seattle Cancer Care Alliance, Seattle

T2N4N2

Tom Baker Cancer Centre, Calgary

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

M4N3M5

Sunnybrook Research Institute, Toronto

H3T1E2

Jewish General Hospital, Montreal

03203

Hospital General Universitario de Elche, Elche

08035

Hospital Universitario Vall d'Hebrón, Barcelona

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY